Drugs / TGFBR2 KO iC9/TROP2.CAR/IL-15 NK cells
Follow
re-read 2 minutes ago
TGFBR2 KO iC9/TROP2.CAR/IL-15 NK cells
Cell therapy targets TGFBR2 via inhibition
Trials 1 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT07553390 | Oct 2026 → Mar 2036 expected | breast cancer | M.D. Anderson Cancer Center | Not yet recruiting | No outcome recorded |
Evidence & citations 5 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | TGFBR2 KO iC9/TROP2.CAR/IL-15 NK cells | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07553390 ↗ |
| Action | Inhibit | “TGFBR2 KO” NCT07553390 ↗ |
| Modality | Cell therapy | “CAR.TROP2/IL15-transduced / TGFBR2KO CB-NK cells” NCT07553390 ↗ |
| Route | Intravenous | “Given by IV” NCT07553390 ↗ |
| Target | TGFBR2 | “TGFBR2 KO” NCT07553390 ↗ |